ERBB2 and breast carcinoma: Additionally, findings from the KATHERINE trial (NCT01772472) indicated that adjuvant treatment with T‐DM1 reduced the risk of recurrence of invasive disease or death by 50% compared with continuing adjuvant trastuzumab among patients with HER2‐positive early breast cancer and residual invasive disease after neoadjuvant chemotherapy plus HER2‐targeted therapy.107